A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ertugliflozin (Primary) ; Metformin
Indications Heart failure; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms ERTU-GLS
Sponsors Merck Ltd. Korea

Most Recent Events

10 Aug 2023 Status changed from recruiting to completed.
16 Aug 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.
16 Aug 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight